Photocure ASA

Remuneration Information • Mar 30, 2023

Photocure ASA - Share option grant

Photocure ASA - Share option grant

Oslo, Norway, 30 March 2023 - Photocure ASA (the "Company") (OSE: PHO) has

granted share options to employees.

A total of 33,900 share options, equal to 0.12% of total shares issued in the

Company, were granted at an exercise price at NOK 85.78. The exercise price is

equal to the weighted average share price 30 trading days before day of grant

with an additional premium of 10% on top of the calculated average price.

All of the options have been granted to employees. The options are granted in

accordance with Photocure's long term incentive program.

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

Email: ed@photocure.no

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com or www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the

market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading

Act.